Impax Laboratories Not Moving Much Despite FDA Approval (IPXL)
Impax Laboratories, Inc. (NASDAQ: IPXL) isn't moving much today, despite receiving final FDA approval for generic Doryx 75 and 100mg tablets this morning.
At last check, shares of IPXL were up 10 cents to $20.60, a gain of 0.5%. It appears that investors had been betting all along that generic Doryx was going to be approved in pill form by the FDA, hence the small reaction in shares.
Impax Laboratories engages in the development and commercialization of bioequivalent and brand-name pharmaceuticals.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.